Chargement en cours...
Nivolumab Induced Multiple Endocrinopathies; Adrenal Insufficiency and Primary Hypothyroidism in a Patient With Stage IV Gastric Cancer - A Case Report
Introduction: Nivolumab is a revolutionary immune check point inhibitor (ICI) that changed the world of oncology. It prevents interaction of Program Death Receptor-1 (PD-1) and Program Death Ligand-1 (PD-L1) releasing a cascade of anti-tumor response. However, it has been associated with wide range...
Enregistré dans:
| Publié dans: | J Endocr Soc |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Oxford University Press
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8265748/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvab048.293 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|